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Serum 25-hydroxyvitamin D [25(OH)D] is often deﬁcient (<12 ng/ml) or insufﬁcient
(<20 ng/ml) in youth living with human immunodeﬁciency virus type 1 infection (YLH).
Based on evidence from multiple genome-wide association studies, we hypothesized that
genetic factors associated with 25(OH)D deﬁciency should be readily detectable in YLH
even when controlling for other known factors, including use of the antiretroviral drug
efavirenz (EFV). Genotyping by bi-directional sequencing targeted 15 single nucleotide
polymorphisms (SNPs) at the GC /DBP locus, with a focus on coding and regulatory
variants, as well as those repeatedly reported in the literature. Three intronic SNPs
(rs222016, rs222020, and rs222029) in a conserved haplotype block had unequivocal
association signals (false discovery rate ≤ 0.006). In particular, the minor allele G for
rs222020 was highly unfavorable among 192YLH (99 African–Americans and 93 others), as
gauged by relatively low likelihood for 25(OH)D sufﬁciency at enrollment (odds ratio = 0.31,
p = 9.0 × 10−4). In a reducedmultivariable model, race, season, latitude, body mass index,
exposure to EFV, and rs222020-G were independent factors that collectively accounted for
38% of variance in the log10-transformed 25(OH)D concentration (p < 0.0001). Interaction
terms were evident for rs222020-G × season (p < 0.001), latitude × season (especially
fall and winter; p < 0.01), and race × EFV use (p = 0.024). Overall, variance in
serum 25(OH)D is substantially attributable to multiple factors, but the exact contribution
of genetic and non-genetic factors can be obscured by partial overlaps and frequent
interactions.
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INTRODUCTION
The vitamin D pathway has a wide range of pathophysiolog-
ical implications, with documented roles in bone metabolism,
renal function, cardiovascular disease, and immune responses
(Chocano-Bedoya and Ronnenberg, 2009; Ramagopalan et al.,
2009; Razzaque, 2009). In the U.S. general population, sub-
optimal serum 25-hydroxyvitamin D [25(OH)D] concentration
(<20 ng/ml)] is highly prevalent (Looker et al., 2008; Ginde et al.,
2009). Factors associated with serum 25(OH)D status include race
(skin color), seasonal (environmental) ﬂuctuation, behavior, and
genetic pre-disposition (Zwart et al.,2007; Bouillon,2010; Bu et al.,
2010; Karohl et al., 2010; Rosen, 2011; Schlingmann et al., 2011;
Vimaleswaran et al., 2013).
Suboptimal serum 25(OH)D is seen in 54% of youth
living with human immunodeﬁciency virus type 1 (HIV)
infection (YLH; Havens et al., 2012a,b). The problem with
25(OH)D insufﬁciency (<20 ng/ml) or deﬁciency (<12 ng/ml)
can be exacerbated by long-term use of antiretroviral drugs,
especially efavirenz (EFV) that is known to interfere with
25(OH)D metabolism (Childs et al., 2012; Panayiotopoulos
et al., 2013). Longitudinal data from YLH with and with-
out vitamin D supplementation can provide an important
platform for dissecting multifactorial inﬂuences on the vita-
min D pathway, including pre-vitamin D transport mediated
by the vitamin D-binding protein (VDBP; Schlingmann et al.,
2011).
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TheGC/DBP gene1 encodingVDBP ismapped to chromosome
4q12-q13, with hundreds of known single nucleotide polymor-
phisms (SNPs). When 25(OH)D concentration is analyzed as a
trait for vitamin D status, both genome-wide association studies
(Wang et al., 2010) and candidate gene approaches (Bu et al., 2010)
have consistently pointed to the potential importance of GC SNP
variants. In an attempt to conﬁrm the GC genotypes associated
with 25(OH)Ddeﬁciency, ourworkhere provides further evidence
to justify ﬁne-mapping for the GC locus in YLH populations.
MATERIALS AND METHODS
STUDY POPULATION
YLH (18–25 years old) represented two self-identiﬁed racial
groups (African–American (AAs) and others) participating in a
randomized, double-blind, placebo-controlled, multicenter trial
(NCT004904122) within the Adolescent Medicine Trials Network
for HIV/AIDS Interventions (ATN; Havens et al., 2012a,b). The
research protocols, including procedures for written informed
consent, were approved by the Institutional Review Board (IRB)
at 16 ATN clinics and 19 International Maternal Pediatric Ado-
lescent AIDS Clinical Trials (IMPAACT) sites in the United States
and Puerto Rico. Ancillary studies summarized here were further
approved by the IRB at University of Alabama at Birmingham
(UAB).
INTERVENTION AND OUTCOME MEASURES
All participants were treated with ≥3 antiretrovirals (ARVs)
for ≥90 days and with plasma HIV-1 RNA (viral load)
<5,000 copies/mL within 60 days. After screening, subjects free
of renal disease, pregnancy, and medicines that may affect bone
mineral density, interfere with vitamin D absorption, or cause
renal toxicity were enrolled into two relatively equal groups based
on their ARV regimens (with or without tenofovir disoproxil
fumarate, TDF).Within each group, eligible participants were ran-
domized to receive vitamin D supplementation or placebo every
4 weeks for three doses. Serum 25(OH)D concentration was mea-
sured at baseline (week 0) and at study week 12 as the primary
outcomes for analyses here.
CANDIDATE LOCI AND GENOTYPING
Earlier reports on phenotypes related to vitamin D (Bu et al.,
2010; Wang et al., 2010; Levin et al., 2012), including bone min-
eral density and fracture (Cho et al., 2009; Richards et al., 2009;
Rivadeneira et al., 2009), have revealed various loci with mod-
est associations (as judged by effect sizes instead of p values).
For this study, SNP selection focused on the most promising
GC/DBP locus that encodes vitamin D-binding protein. SNPs
reported repeatedly in the literaturewere considered ﬁrst, followed
by ﬂanking SNPs (to facilitate analysis of linkage disequilibrium,
LD) and SNPs found in coding and regulatory sequences. Using
DNA extracted from Isohelix buccal swabs (Cell Projects Ltd.,
Kent, UK), all SNP genotypes were resolved by bi-directional
DNA sequencing using the gold-standard Sanger chemistry (Poly-
morphic DNA Technologies, Inc., Alameda, CA, USA). For SNPs
1http://www.ncbi.nlm.nih.gov/gene/2638
2http://clinicaltrials.gov/ct2/show/NCT00490412
with minor allele frequencies (MAF) exceeding 0.05, the pair-
wise LD patterns were tested using the HaploView program
(Barrett et al., 2005).
STATISTICAL ANALYSES
The study population was ﬁrst grouped by race (AAs vs. others)
for comparison of baseline (week 0) characteristics, withWilcoxon
test, Student t-test, and Chi-squared test applied to appropri-
ate measurements. Subsequent analyses focused on three speciﬁc
aims. Aim 1 was to demonstrate that serum 25(OH)D concen-
tration is a relatively stable phenotype in YLH. Measurements at
baseline and at week 12 were compared in participants in the
placebo group (who did not receive vitamin D supplementation),
using Spearman method (rho) and Pearson’s correlation coefﬁ-
cient (r; before and after log10-transformation/ “normalization,”
respectively). Aim 2 was to identify individual SNP genotypes
associated with three clinically relevant 25(OH)D categories at
baseline: <12 ng/ml (deﬁciency), ≥12–<20 ng/ml (insufﬁciency)
and >20 ng/ml (sufﬁciency), using the ordinal logistic regres-
sion models adjusted for non-genetic factors (age, sex, and race).
All relationships with statistical signiﬁcance (p < 0.05) and low
false discovery rate (FDR; q < 0.05) were included in multivari-
able models. Aim 3 was to quantify multifactorial inﬂuences on
serum 25(OH)D, when log10-transformed serum 25(OH)D was
analyzed as a continuous outcome in generalized linear models
(GLMs). The summary statistics focused on relative effect sizes
(regression beta andR2 values) attributable to genetic factors (SNP
genotypes), demographic features (age, sex, and race), body mass
index (BMI), environmental factors (season and latitude), and
exposure to EFV. Similar approaches have been applied earlier to
analyses of quantitative traits related to HIV infection (Yue et al.,
2013). Whenever possible, secondary (exploratory) models were
evaluated for AAs and other races separately.
RESULTS
CHARACTERISTICS OF STUDY POPULATION BY RACE
A total of 192 YLH subjects had sufﬁcient data for analyses, with
relative equal representation of AAs (n = 99) and others (n = 93;
Table 1). At baseline (week 0), these groups were similar (p> 0.20)
in terms of age, female to male sex ratio (0.62 vs. 0.58), latitude of
residency, enrollment seasons, randomization to vitamin D sup-
plementation (49.5 vs. 52.3%), exposure to EFV (45.5 vs. 37.6%),
and CD4+ T-cell (CD4) count (505 ± 149 vs. 550 ± 224 cells/μl
of blood). In addition, similar proportions of AAs (13.0%) and
others (17.5%) had severe immunodeﬁciency at baseline (CD4
count< 350 cells/μl). On the other hand,AAs differed fromothers
in serum 25(OH)D concentrations both at baseline (p < 0.0001)
and at week 12 (p < 0.01).
STABILITY OF SERUM 25(OH)D CONCENTRATION OVER A 12-WEEK
PERIOD
In a subset of subjects (46 AAs and 42 others) who were ran-
domized to the placebo group, log10-transformed 25(OH)D
concentrations were moderately stable between the two visits
regardless of race (Figure 1), with Pearson r values ranging from
0.73 in AAs (p < 0.0001) to 0.77 in others (p < 0.0001; p > 0.50
between the two r values). Statistical adjustments for other factors
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Table 1 | Main characteristics of the study population, after stratification by race/ethnicity.
Characteristicsa AAs (n = 99) Others (n = 93) Pe
Enrollment season: n (%)
Winter 23 (23.2) 18 (19.4)
Spring 30 (30.3) 32 (34.4)
Summer 24 (24.3) 23 (24.7)
Fall 22 (22.2) 20 (21.5)
At baseline (week 0)
Age (year): mean ± SD 20.8 ± 2.0 20.9 ± 2.0 –
BMI (kg/m2): mean ± SD 26.3 ± 7.7 24.5 ± 5.5 0.058
Sex ratio (F/M) 0.62 (38/61) 0.58 (34/59) –
Latitude: n (%) 0.067
≤35◦ 30 (30.3) 41 (44.1)
>35◦ and ≤40◦ 26 (26.3) 14 (15.0)
>40◦ 43 (43.4) 38 (40.9)
25(OH)D (ng/ml): median (IQR) 14.7 (10.0 − 21.0) 23.8 (17.4 − 29.9) <0.0001f
log10 25(OH)D: mean ± SD 1.17 ± 0.23 1.37 ± 0.19 <0.0001
25(OH)D < 20 ng/ml: n (%) 71 (71.7) 32 (34.4) <0.0001
Vitamin D supplementation (50,000 U/month) 49 (49.5) 49 (52.7) –
Exposure to EFV: n (%) 45 (45.5) 35 (37.6) –
CD4 count (cells/μl): mean ± SDb 505 ± 149 550 ± 224 –
CD4 < 350 cells/μl: n (%)b 7 (13.0) 10 (17.5) –
At week 12
25(OH)D (ng/ml): median (IQR) 24.3 (15.2 − 30.7) 27.3 (22.2 − 36.3) 0.005f
log10 25(OH)D: mean ± SD 1.34 ± 0.26 1.46 ± 0.19 0.0006
25(OH)D < 20 ng/ml: n (%) 33 (35.9) 17 (18.7) 0.009
CD4 count (cells/μl): mean ± SDc 521 ± 161 617 ± 280 0.051
CD4 < 350 cells/μl: n (%)c 5 (11.6) 6 (12.2) –
Between visitsd
Stability of 25(OH)D: rho (p) 0.69 (<0.0001) 0.63 (<0.0001) –
Stability of log10 25(OH)D: r (p) 0.73 (<0.0001) 0.77 (<0.0001) –
aAAs, African–Americans; BMI, body mass index; F, female; M, male; 25(OH)D, serum 25-hydroxyvitamin D concentration; IQR, interquartile range; SD, standard
deviation of the mean; EFV, efavirenz; CD4 count, CD4+ T-cell count in peripheral blood.
bPartial data for 54 AAs and 57 others at week 0.
cPartial data for 43 AAs and 49 others at week 12.
d Restricted to the subset of subjects (46 AAs and 42 others) randomized to the placebo group. Six subjects (four AAs and two others) are excluded because of
missing data at week 12.
eAll p values > 0.20 are omitted (–).
f By Wilcoxon test; all other comparisons are done with t-test and Chi-squared test.
slightly improved the r values. For example, when season was
treated as a covariate, the adjusted r value became 0.74 in AAs
(p < 0.0001) and 0.83 in others (p < 0.0001; p = 0.322 between
the two adjusted r values). For 25(OH)D concentrations without
log10-transformation, rank correlation between visits (Spearman
rho values) ranged from 0.69 in AAs (p < 0.0001) to 0.63 in others
(p < 0.0001; p > 0.50 between the two rho values).
SCREENING FOR INFORMATIVE GC SNPs
DNAsequencing based on 91 sampleswithmostDNA (47AAs and
44 others) identiﬁed 15 informative SNPs with MAF ≥ 0.05 in the
overall study population (Table 2). All but one SNP (rs114282916)
showed differential distribution between the two racial groups
(AAs and others). Most SNPs had weak pairwise LD in both
racial groups, but three intronic SNPs (rs222016, rs222020, and
rs222029) were within a conserved haplotype block (Figure 2).
Additional SNPs dismissed based on rarity of minor alleles (sin-
gleton to MAF < 0.05) included rs9016, rs3737553, rs80324156,
rs114737000, rs6843222, and 10 polymorphisms not captured in
the dbSNP database (last accessed in April 2013).
In univariablemodels testing three clinically relevant 25(OH)D
levels at baseline: <12 ng/ml (deﬁciency), ≥12–<20 ng/ml
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FIGURE 1 | Stability of serum 25-hydroxyvitamin D [25(OH)D]
concentration (ng/ml) in 88 HIV-1-infected youth who did not receive
randomized vitamin D supplementation over a 12-week period.
Measurements at baseline (week 0) and at study week 12 are shown for 46
African–Americans (AAs) and 42 non-AA subjects (others). The predicted
slope and its 95% conﬁdence intervals in each subgroup are represented
by sold and dotted lines, respectively. Six subjects (four AAs and two
others) with missing data at week 12 are excluded.
(insufﬁciency), and >20 ng/ml (sufﬁciency), seven SNPs showed
promising trend (p < 0.05 and q ≤ 0.10) for associations in
dominant models, with proportional odds ratios (pOR) rang-
ing from 0.17 (rs222016 and rs222020, unfavorable) to 3.41
(rs7041, favorable) and q values from 0.002 (rs222016 and
rs222020) to 0.10 (rs35096193, favorable; Table 3). Among
the top four SNPs with q < 0.05, rs7041 has known asso-
ciations with vitamin D status and related outcomes (Fang
et al., 2009; Wood et al., 2011). Three other SNPs in strong
LD (Figure 2) could be represented by rs222020, which has
been associated with vitamin D status and related outcomes as
Table 2 | Minor allele frequency for 15 GC SNPs resolved by DNA
sequencing.
SNP IDa Alleles Location Minor allele frequency
Overall African–
Americans
Others
rs4588b C/A Exon 11 0.177 0.112 0.247
rs7041b T/G Exon 11 0.310 0.143 0.489
rs112205706 G/A Intron 0.053 0.098 0.011
rs222016 A/G Intron 0.383 0.565c 0.205
rs222020b A/G Intron 0.385 0.535c 0.226
rs222029 A/G Intron 0.325 0.467 0.182
rs2298849 A/G Intron 0.309 0.391 0.227
rs3733359 G/A Promoter 0.184 0.255 0.102
rs35096193 G/T Promoter 0.210 0.087 0.341
rs1565572 G/T Promoter 0.479 0.282 0.670c
rs114282916 C/T Promoter 0.105 0.117 0.102
rs115617005 T/C Promoter 0.051 0.107 0
rs76884743 A/T Promoter 0.053 0.096 0.011
rs113387725 C/T Promoter 0.163 0.213 0.102
rs80061752 C/T Promoter 0.053 0.096 0.011
aSorted by location on chromosome 4q (see Figure 2 ). Six more known SNPs
(rs9016, rs3737553, rs80324156, rs114737000, rs6843222, and rs71213589) are
dismissed for rarity of their minor alleles.
bThese SNPs are sequenced for the entire cohort, while others are dropped after
the screening phase (based on patterns of linkage disequilibrium and estimates
of statistical power).
cMinor and major alleles are switched between the two racial groups.
well (Bu et al., 2010; Xu et al., 2010; Jung et al., 2011; Zhang
et al., 2012). Further genotyping in the rest of the study cohort
focused on rs7041 (a coding SNP) and rs222020 (an intronic
SNP).
UNIVARIABLE AND MULTIVARIABLE MODELS FOR TWO GC SNPs
(rs222020 and rs7041) IN THE ENTIRE COHORT
Both rs7401-G and rs222020-G were associated with baseline
serum 25(OH)D categories in univariable models (pOR = 2.32
and 0.31, p = 0.008 and 9.0 × 10−4, respectively). After statis-
tical adjustment for demographic features (sex, age, and race)
and exposure to EFV, rs7041 allele G was no longer a predictor
(adjusted pOR = 1.08 and p = 0.827), while rs222020 allele G
remained predictive of serum 25(OH)D categories (pOR = 0.45
and p = 0.014). However, further adjustments for BMI and envi-
ronmental factors (latitude and enrollment season) diminished
the association of rs222020-G (adjusted p = 0.069; Table 4). The
strong independent predictors included race (p < 0.0001), enroll-
ment season (p < 0.0001), latitude of residence (p < 0.001),
BMI (p = 0.002), and use of EFV (p = 0.006). Summer had
the most dramatic impact on seasonal ﬂuctuation in serum
25(OH)D (pOR = 8.23, p < 0.0001), while fall and spring
were also quite favorable against winter (pOR = 4.90 and 3.55,
respectively).
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FIGURE 2 | Patterns of pairwise linkage disequilibrium (LD)
among 15 GC SNPs used for screening and estimating
statistical power. Each pairwise comparison of SNP genotypes
(deﬁned by direct sequencing) is captured by an r2 value (×100).
Similar results are obtained from analyses of SNP genotypes in
AAs and other races (excluding SNPs rs112205706 and
rs115617005). By default, absolute LD (r2 = 1.00) is indicated by
a dark square.
VARIANCE IN log10-TRANSFORMED SERUM 25(OH)D CONCENTRATION
EXPLAINED BY GC GENOTYPES AND OTHER PERTINENT FACTORS
At least six factors independently contributed to the variability
in log10-transformed serum 25(OH)D concentration (Table 5).
When sorted by their relative impact (i.e., beta estimate and
semi-partial R2 value), race (AAs vs. other), and season had
the greatest effects (adjusted p < 0.0001 and p < 0.001, respec-
tively), followed by latitude (in three major grids; p < 0.001),
BMI (p = 0.008), use of EFV (p = 0.016), and rs222020-G
(p = 0.023). Collectively, these factors accounted for 38.0% of
variance in the log10-transformed 25(OH)D concentration at
baseline (p < 0.0001). Other potential factors, including sex, age,
and additional GC SNP variants were ﬁrmly dismissed (adjusted
p > 0.25).
Ranking of the six individual (independent) predictors of
log10-transformed serum25(OH)D concentrationwas often com-
plicated by issues with partial overlap. For example, variance
explained by the rs222020-G allele varied substantially (from
2.9 to 10.7%) according to the order in which three partially
overlapping factors (race, use of EFV, and rs222020-G) were
added to the model. In addition, the variance attributable to
rs222020-G differed somewhat between AAs (4.5%, adjusted
p = 0.029) and others (3.3%, adjusted p = 0.080) when con-
ditioned on the effect of EFV (Table 7). In contrast, after
accounting for the effect of rs222020-G, the impact of EFV use
on 25(OH)D was only apparent in AAs (adjusted R2 = 8.8%,
p = 0.003) and not in others (adjusted R2 = 0.1%, p = 0.812;
Table 7).
INTERACTION TERMS
Multivariable models further revealed several pairwise interac-
tions, i.e., rs222020-G × season (p < 0.001), latitude × season
(especially fall and winter; p < 0.01), and race × EFV use
(p = 0.024). Seasonality of the rs222020-G effect on 25(OH)Dwas
apparently restricted to spring, as genotype-speciﬁc differences
were not detected in other seasons (Figure 3).
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Table 3 | Univariable analyses of seven GC SNPs using baseline (week
0) serum 25(OH)D concentration as three ordinal categories
(deficiency, insufficiency, and sufficiency).
GC SNP genotypes n (AA + other) pORa p FDR
(q)c
rs7041 (GG + GT vs. TT) 90 (46 + 44) 3.41 0.003 0.010
rs222016b (GG+AG vs. AA) 90 (46 + 44) 0.17 0.0003 0.002
rs222020b (GG + AG vs. AA) 91 (47 + 44) 0.17 0.0002 0.002
rs222029b (GG + AG vs. AA) 90 (46 + 44) 0.24 0.001 0.006
rs35096193 (TT +TG vs. GG) 90 (46 + 44) 2.35 0.047 0.100
rs76884743 (TT + AT vs. AA) 91 (47 + 44) 0.24 0.025 0.060
rs80061752 (TT +TC vs. CC) 91 (47 + 44) 0.24 0.025 0.060
aFavorable effect (association with vitamin D sufﬁciency) is reﬂected by a value
of >1.0 for the proportional odds ratio (pOR).
bThese SNPs form a single haplotype block regardless of racial background (see
Figure 2 ).
cFalse discovery rate (FDR) is based on p values from analyses of all 15 SNPs
shown inTable 2 .
OBSERVATION OF DIFFERENCES BETWEEN RACIAL GROUPS
At least two racial differences were noted in separate analyses of
AAs (n = 99) and other races (n = 93). First, negative association
of rs222020-G with 25(OH)D was restricted to AAs (R2 = 4.5%,
adjusted p = 0.029) and not other subjects (3.3%, adjusted
p = 0.080) when conditioned on the effect of EFV (Table 7).
Second, the deleterious impact of EFV use on 25(OH)D was seen
in AAs (adjusted R2 = 8.8%, p = 0.003) and not in other sub-
jects (adjusted R2 = 0.1%, p = 0.812) after accounting for the
contribution of rs222020-G.
Table 4 | Independent predictors of serum 25(OH)D concentration as
three ordinal categories (deficiency, insufficiency, and sufficiency).
Independent factors Relative effect c in a joint (multivariable)
model
pOR 95% CI p
rs222020-Ga 0.54 0.27 − 1.05 0.069
Being African–American 0.21 0.11 − 0.41 <0.0001
Enrollment season <0.0001
Springb 3.55 1.53 − 8.20 0.003
Summerb 8.23 3.22 − 21.04 <0.0001
Fallb 4.90 1.98 − 12.15 <0.0001
Latitude of residence (trend) 0.52 0.63 − 0.74 <0.001
Body mass index 0.93 0.88 − 0.97 0.002
Use of efavirenz (EFV) 0.42 0.22 − 0.78 0.006
aNucleotide A is the major allele (referent) for rs222020. In a third model,
rs222020-G accounts for 3.3% of log10 25(OH)D variance in 93 other subjects
(see text).
bWinter is the referent in all tests.
cFavorable effect (association with vitamin D sufﬁciency) is reﬂected by a value
of >1.0 for the proportional odds ratio (pOR).
Table 5 | Independent predictors of baseline (week 0) serum 25(OH)D
concentration among 192 youth living with HIV-1 infection:
alternative analyses after considering environmental factors.
GC variant and
demographic features
Relative impactc on log10 25(OH)D
(multivariable model)
 (Mean ± SE) R2 p
rs222020-Ga −0.07 ± 0.03 0.018 0.023
Being African–American −0.15 ± 0.03 0.089 <0.0001
Use of efavirenz (EFV) −0.07 ± 0.03 0.020 0.016
BMI (per unit change)b −0.01 ± 0.00 0.025 0.008
Latitudeb −0.06 ± 0.02 0.045 <0.001
Seasonb NA 0.073 <0.001
Spring vs. winter 0.12 ± 0.04 NA 0.003
Summer vs. winter 0.19 ± 0.04 NA <0.0001
Fall vs. winter 0.13 ± 0.04 NA 0.002
aThe AA genotype is treated as the referent for rs222020 allele G.
bAs deﬁned inTable 1.
cFor each individual factor, the independent (adjusted) effect size is measured
ﬁrst by the difference () in serum log10 25(OH)D and then by the R2values (all
are under-estimated because of partial overlap). For the overall model, R2 = 0.380
(p < 0.0001).
DISCUSSION
Despite a modest sample size, our analyses here reveal ﬁve major
ﬁndings concerning vitamin D metabolism in youth living with
HIV-1 infection. First, serum 25(OH)D concentration is relatively
stable over a 12-week period regardless of race. Second, at least one
GC SNP variant, the rs222020-G allele, is independently predic-
tive of suboptimal serum 25(OH)D, especially during the spring
Table 6 |Three independent interaction terms identified by
multivariable analyses.
Interaction termsa Relative impactd on log10 25(OH)D
(multivariable model)
 (mean ± SE) R2 P
rs222020-G × season NA 0.055 <0.001
rs222020-G × springb −0.22 ± 0.05 NA <0.001
Latitude × season NA 0.026 0.035
Latitude × fallc −0.11 ± 0.03 NA <0.001
Latitude × winterc −0.10 ± 0.03 NA 0.002
Use of EFV × race NA 0.015 0.024
aNon-interactive factors (e.g., BMI) are also included in the model. The AA geno-
type is treated as the referent for rs222020.
bSeasonality of the rs222020-G effect is restricted to spring.
cTwo seasons (fall and winter) capture the main interactive effect of latitude ×
season.
d For each interaction term, the independent effect size is measured ﬁrst by
the difference () in serum log10 25(OH)D and then by the R2values (all are
under-estimated because of partial overlap).
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Table 7 | Examples of racial differences in genetic association with
serum 25(OH)D concentration.
GC variant and two
other factors
Relative impactc on log10 25(OH)D
(multivariable model)
 (Mean ± SE) R2 P
Overall cohort (N = 192)
rs222020-Ga −0.09 ± 0.03 0.033 0.004
Being African–American −0.17 ± 0.03 0.113 2.9 × 10−7
Use of efavirenz (EFV) −0.07 ± 0.03 0.021 0.024
African–Americans only (n = 99)
rs222020-Ga −0.12 ± 0.05 0.045 0.029
Use of efavirenz (EFV)b −0.14 ± 0.04 0.088 0.003
Others only (n = 93)
rs222020-Ga −0.07 ± 0.04 0.035 0.071
aHomozygosity with the major allele A serves as the referent for rs222020.
bNot a statistically signiﬁcant factor in the model for other races (adjusted
R2 = 0.001, p = 0.812).
cFor each factor shown in individual models, the independent effect size is mea-
sured ﬁrst by the difference () in serum log10 25(OH)D (the reference group is
negative for all factors) and then by the R2 values.
season. Third, use of EFV is associated with low serum 25(OH)D
in the combined cohort based on univariable models, but the EFV
effect is restricted to AAs when the rs222020-G allele is added to
multivariable models. Fourth, the exact contribution of genetic
and non-genetic factors (latitude, season, BMI, and race) can
be obscured by partial overlaps and frequent interactions. Fifth,
statistical models are not uniformly applicable to racial groups.
Most of these observations are novel and highly relevant to public
health.
As a main focus of this study, the GC gene3 consists of 13
exons and has hundreds of known SNPs, but neither genome-
wide association studies nor candidate gene approaches reported
in the literature have covered this locus sufﬁciently enough to
allow ﬁne-mapping. To avoid heavy penalty for multiple test-
ing of randomly selected GC SNPs, we chose to examine coding
and regulatory (promoter) sequences at both ends of several
SNPs with relatively consistent associations. For example, the
minor allele G (or C in the complementary strand) for rs222020
has been highlighted recently in the context of compression
strength index of the femoral neck (Xu et al., 2010), periph-
eral arthritis in ankylosing spondylitis (Jung et al., 2011), and
plasma 25(OH)D concentration (Zhang et al., 2012). By analyz-
ing rs222020 and multiple neighboring SNPs, it was evident that
rs222020-G is able to tag several intronic variants within a sin-
gle haplotype block. However, rs222020-G did not seem to tag
other functionally relevant variants. Mechanisms underlying its
independent association with suboptimal 25(OH)D concentra-
tion remain elusive, and search for further clues may need to
consider less obvious pathways (DNA–DNA and DNA–protein
interactions) being actively pursued by the ENCODE project
3http://www.ncbi.nlm.nih.gov/gene/2638
FIGURE 3 | Season-dependent association of GC genotypes with
serum 25-hydroxyvitamin D [25(OH)D] concentration.The
log10-transformed 25(OH)D (ng/ml) values in 192 HIV-1-infected youth are
plotted according to four enrollment seasons and three genotypes deﬁned
by the GC SNP, rs222020 (major allele A and minor allele G). For each
stratum, the horizontal bars connected by a vertical line correspond to the
mean ± standard deviation (SD). The nominal p values are based on
Student’s t -test, assuming a dominant effect of allele G (seeTable 6 for full
analyses of interactions between rs222020-G and enrollment season).
(Dunham et al., 2012; Harrow et al., 2012; Rosenbloom et al., 2012;
Wang et al., 2013).
Two other prominent GC SNPs, rs7041, and rs4588, do cause
amino acid substitutions at codon 416 (D/E) and codon 420
(T/K), respectively, in exon 11. Three haplotypes involving these
non-synonymous SNPs correspond to different protein isoforms
known as GC1F, GC1S, and GC2. Earlier studies have demon-
strated the potential importance of rs7041 variants alone (Wood
et al., 2011) or in conjunction with rs4588 variants (Fang et al.,
2009). Although rs7041-G appeared to be highly favorable in
our initial screening (univariable models only), it was subse-
quently dismissed by multivariable models in which race and
other prominent factors were treated as covariates. The distri-
bution of rs7041-G differs between AAs (low) and other races
(high; Table 2), so deﬁnitive analyses may require a third popu-
lation with intermediate allele frequency. Nonetheless, rs7041-G
may serve as a useful biomarker for disparity in serum 25(OH)D
concentration, especially since its biological relevance is so obvi-
ous. Additional GC SNPs of interest, including rs2070741 (Wood
et al., 2011) and rs2282679 (Vimaleswaran et al., 2013), are not
part of our study design. Judging by their reported effect sizes,
it is unlikely that inclusion of these SNPs will alter our main
conclusions.
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Our ﬁnding onGC SNP rs222020 here is highly consistent with
earlier observations based on two independent Caucasian popu-
lations (Bu et al., 2010). The effect size (R2) reported for rs222020
ranges from 1% to 4% in Caucasians, which is quite similar to
what we can demonstrate for YLH (Table 5). However, by our
assessment, the association of rs222020 genotypes with 25(OH)D
concentration is heavily dependent on seasonal ﬂuctuation. Stud-
ies that evaluate subjects in the spring season alone can lead to
over-estimates, while analyses biased for other seasons can eas-
ily miss the genetic effect (Table 6; Figure 3). Future studies will
clearly need to consider the strong impact of season and latitude
on vitamin D metabolism.
Recognition of EFV as another factor that inﬂuences vitamin
D metabolism is also well expected (Childs et al., 2012; Havens
et al., 2012a). Of note, the unfavorable impact of EFV was mostly
restricted to AAs. Such racial disparities may reﬂect the sensitivity
or vulnerability of AAs to therapeutic complications when they
are already prone to having suboptimal 25(OH)D concentration.
Fortunately, response to vitamin D supplementation is not com-
promised by use of EFV (Havens et al., 2012a). Further elucidation
of race-speciﬁc effects of EFV will need to rely on large cohorts
with prospective data.
In summary, our study identiﬁed at least six partially over-
lapping but independent factors that collectively account for
38% of variance in serum 25(OH)D concentration. The com-
plex picture can attest to the need for cautionary interpretation
of results from univariable models, as exempliﬁed by analy-
sis of GC SNPs rs7401 and rs222020. Fine-mapping of the
GC locus for causal variants is more difﬁcult than expected
because (i) rs222020-G and related GC variants are not in clear
LD with coding and promoter sequence polymorphisms; (ii)
the effect of rs7041-G is clearly confounded by racial back-
ground, and (iii) serum 25(OH)D concentration as a quantitative
or semi-quantitative trait can ﬂuctuate over time (seasonal-
ity). These observations should beneﬁt follow-up studies on
GC genotypes and vitamin D metabolism, probably beyond
the setting of chronic HIV infection and long-term therapeutic
complications.
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